CA125 Protein - ACROBiosystems

Home
Products

Products by Category

Recombinant proteins and more
Multi-pass Transmembrane Proteins and Technology PlatformsNew FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew CytokinesHot Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins

Pre-labeled proteins
CAR rapid detection reagentsStar Staining Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum Samples Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 mutant productsNew
Others
Multi-pass Transmembrane Proteins and Technology PlatformsNew Claudin18.2 ProteinsNew Bispecific antibody targetsHot Targets for ADCsHot IL-2 and IL-2 Receptor ProteinsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Services

Innovation Lab
SPR /BLI analytical serviceNew Anti-Idiotypic AntibodyNew Enzyme-Linked Immunosorbent Assay (ELISA) Service New Meso Scale Discovery (MSD) ServiceNew
Licensing Opportunities
Anti-TIM-3 monoclonal antibody New Anti-LAG-3 monoclonal antibody New Target 4-1BB monoclonal antibody New PD-1/CD80 bispecific antibodyNew Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1New Anti-PD-L1 / TIGIT bispecific antibodyNew
Supports

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA FAQ
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

CA125

Brief Information

Name:Mucin-16
Target Synonym:Mucin-16 Short Isoform,Mucin-16 Long Isoform,Ovarian carcinoma antigen CA125,Ovarian cancer-related tumor marker CA125,MUC16,MUC-16,CA-125,Mucin 16, Cell Surface Associated,CA125,CA125 Ovarian Cancer Antigen,Mucin-16,CA-125 Antigen,FLJ14303

Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 3 Clinical


CA5-H82F8	Human	Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™
CA5-H82F4	Human	Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™

Cat. No.

Species

Product Description

Structure

Purity

Feature

CA5-H82F8

Human

Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™

CA5-H82F4

Human

Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™

Part of Bioactivity data

CA5-H82F4-ELISA

Immobilized Human Mesothelin, His Tag (Cat. No. MSN-H5223) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CA125, Fc,Avitag (Cat. No. CA5-H82F4) with a linear range of 2-78 ng/mL (QC tested).

Protocol

Synonym Name

CA125, CA-125, CA125MUC-16, FLJ14303, MUC16, mucin 16, mucin-16

Background

The CA125, also known as the MUC16, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions.

Clinical and Translational Updates

Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
JCAR-020	JCAR-020	Phase 1 Clinical	Memorial Sloan Kettering Cancer Center	Ovarian Neoplasms	Details
Oregovomab	B43.13	Phase 3 Clinical	Paladin Pharma	Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma	Details